Red blood cell (RBC) transfusions during surgery are associated with double the risk of venous thromboembolism (VTE) over the ensuing 30 days, researchers reported in JAMA Surgery.
An early discharge strategy with rivaroxaban reduces hospital lengths of stay and healthcare costs for patients with low-risk pulmonary embolism (LRPE)—without compromising their safety—suggests a study published in Academic Emergency Medicine.
The 200 and 250 millimeter lengths of Medtronic’s IN.PACT Admiral drug-coated balloon gained FDA approval to treat long superficial artery (SFA) lesions in patients with peripheral artery disease (PAD), the company announced June 15.
New research suggests flavorings in electronic cigarettes, or e-cigarettes—including mint, vanilla, cinnamon and strawberry—can adversely affect endothelial cells, according to a study published June 14 in Arteriosclerosis, Thrombosis, and Vascular Biology.
Erectile dysfunction (ED) is an independent predictor of cardiovascular disease (CVD), according to a research letter published June 11 in Circulation.
The first coagulation monitoring device with built-in Bluetooth technology is expected to be commercially available this summer to warfarin patients in the United States, according to device-maker Roche Diagnostics.
Minorities, specifically blacks and Hispanics, are more than twice as likely to have a second intracerebral hemorrhage than white counterparts, according to a new study published in Neurology on June 6.
A research team at Worcester Polytechnic Institute in Massachusetts is engineering functioning human blood vessels which can mimic common cardiac and vascular problems, a tool they hope can be used to test new medications more quickly.
A new study published in the Journal of the American Heart Association suggests stroke patients who reach and maintain the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines of 130/80 mmHg, deaths may be cut by 33 percent, compared to the 2014 guidelines.
Updating the 2013 pooled cohort equations (PCEs) with more recent patient populations and new statistical methods results in approximately 11.8 million U.S. adults migrating to a lower-risk category, potentially affecting which therapies they would be indicated for to combat atherosclerosis.
Almost 3 percent of infants and children hospitalized for pediatric arterial ischemic stroke (AIS) die in the hospital, according to a new international study published in the May 2018 edition of Pediatrics.
Restenosis of the carotid arteries is more likely after stenting than endarterectomy and increases the likelihood of stroke, according to a subanalysis of a randomized trial published in The Lancet Neurology.
A compound found in green tea can break up the plaque that causes atherosclerosis, according to research published May 31 in the Journal of Biological Chemistry.
Avinger announced last week the FDA has approved its next-generation Pantheris Lumivascular atherectomy device, which is used to remove plaque from a blood vessel in those with peripheral artery disease (PAD).
In-home physical therapy using telehealth systems, supervised by a licensed physical therapist, is effective for stroke rehabilitation, according to a study presented May 24 at the 2018 European Stroke Organization Conference in Gothenburg, Sweden.
With shorter half-lives and more predictable effects, direct oral anticoagulants (DOACs) could help simplify perioperative treatment decisions for patients with non-valvular atrial fibrillation (NVAF), suggests a meta-analysis published May 24 in Circulation.
Severe and active atopic eczema in adulthood is associated with an increased risk for developing cardiovascular disease (CVD), including stroke, heart failure, myocardial infarction (MI) and atrial fibrillation (AFib), according to a new study published May 23 in The BMJ.
The FDA has cleared a robotic system that can noninvasively assess abnormal blood flow to the brain, helping diagnose and triage patients with ischemic strokes and other neurologic disorders.
Human growth hormone showed the potential to improve the memory and cognitive function of mice post-stroke, raising the possibility of a similar treatment for humans.
Individuals with a combination of vascular risk factors and higher levels of beta-amyloid protein in the brain may be on a speedier path of cognitive decline, suggests a study published May 21 in JAMA Neurology.
